A Study of the Effectiveness of Cabozantinib in Combination With Nivolumab as First-line Treatment of Advanced Renal Cell Carcinoma (aRCC) in Adults
← catalyst calendarSponsored by Ipsen (industry) · IPN.PA — their whole pipeline →.
Phase
—
Status
Completed
Study type
Observational
Enrollment
311actual
Sites
66
Countries
Belgium, France, Greece +5
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-09-26 | actual | When the study began enrolling |
| Primary completion | 2025-10-20 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-10-20 | actual | The whole study's end, after follow-up |
| First posted | 2022-05-04 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-01 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Advanced Renal Cell Carcinoma
Primary outcome
what the primary-completion date above is the date OFOverall survival (OS) rate (death of any cause) from the start of cabozantinib in combination with nivolumab.
measured At 18 months follow up
Publications
- PMID 37403652 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · IPN.PA's whole pipeline · Catalyst calendar · Every registered study · What changed